Follow The CEO? Abbott Chief Chooses Diversified Products, Emerging Markets Over Rx Drugs As Company Splits In Two
This article was originally published in PharmAsia News
Executive Summary
Abbott Laboratories CEO Miles White has complained for a long time that U.S. investors don't understand the growth opportunity of emerging markets. Now White finally has a chance to put his money where his mouth is, choosing to lead a diversified medical products company rather than an innovative pharmaceutical company that will carry a different name, following a decision to split Abbott into two companies
You may also be interested in...
Emerging Markets Earnings Roundup: Abbott (Part 2)
Abbott Laboratories said it has turned a corner after dairy product recalls last year and that China is squarely in focus, but known unknowns remain.
Emerging Markets Earnings Roundup: Abbott (Part 2)
Abbott Laboratories said it has turned a corner after dairy product recalls last year and that China is squarely in focus, but known unknowns remain.
Emerging Markets Earnings Roundup: Abbott, AbbVie, J&J, GSK (Part 3)
After Abbott/AbbVie split, emerging markets represent 40% of Abbott’s sales compared to 15% of AbbVie sales. Abbott, J&J and GSK report dismal sales in Europe, noting that EMs remain a bright spot.